InvestmentJun 10, 2026, 07:51 AM
CervoMed Raises $10.5M in Private Placement for Neflamapimod Development
AI Summary
CervoMed Inc. announced a private placement financing expected to yield approximately $10.5 million in gross proceeds. The financing, which includes participation from company insiders, is intended to fund the research and development of its clinical-stage product candidate, neflamapimod, and extend the company's cash runway into the second quarter of 2027. A strategic priority is to establish a partnership to advance neflamapimod into Phase 3 development for dementia with Lewy bodies. The company also anticipates up to an additional $21.7 million if warrants are fully exercised.
Key Highlights
- CervoMed Inc. secures approximately $10.5 million in a private placement financing.
- The financing includes participation from key insiders, including the Chair and CEO.
- Proceeds will fund research and development of neflamapimod and extend cash runway into Q2 2027.
- Company aims to establish a strategic partnership to advance neflamapimod into Phase 3 for Dementia with Lewy Bodies.
- Potential for an additional $21.7 million if warrants are fully exercised.
- Upcoming milestones include Phase 2a data for neflamapimod in PPA and initiation of an ALS trial.
Price Impact
More from CRVO